title: A Novel and Validated Inflammation-Based Score (IBS) Predicts Survival in Patients With Hepatocellular Carcinoma Following Curative Surgical Resection: A STROBE-Compliant Article.
abstract: As chronic inflammation is involved in the pathogenesis and progression of hepatocellular carcinoma (HCC), we investigated the prognostic accuracy of a cluster of inflammatory scores, including the Glasgow Prognostic Score, modified Glasgow Prognostic Score, platelet to lymphocyte ratio, Prognostic Nutritional Index, Prognostic Index, and a novel Inflammation-Based Score (IBS) integrated preoperative and postoperative neutrophil to lymphocyte ratio in 2 independent cohorts. Further, we aimed to formulate an effective prognostic nomogram for HCC after hepatectomy.Prognostic value of inflammatory scores and Barcelona Clinic Liver Cancer (BCLC) stage were studied in a training cohort of 772 patients with HCC underwent hepatectomy. Independent predictors of survival identified in multivariate analysis were validated in an independent set of 349 patients with an overall similar clinical feature.In both training and validation cohorts, IBS, microscopic vascular invasion, and BCLC stage emerged as independent factors of overall survival (OS) and recurrence-free survival (RFS). The predictive capacity of the IBS in both OS and RFS appeared superior to that of the other inflammatory scores in terms of C-index. Additionally, the formulated nomogram comprised IBS resulted in more accurate prognostic prediction compared with BCLC stage alone.IBS is a novel and validated prognostic indicator of HCC after curative resection, and a robust HCC nomogram including IBS was developed to predict survival for patients after hepatectomy.
authors.affiliation: From the Liver Cancer Institute, Zhongshan Hospital and Shanghai Medical School (Y-PF, X-CN, YY, X-YC, H-WH, J-XW, Z-FL, JZ, JF, S-JQ) and Biomedical Research Center, Zhongshan Hospital (XH, S-JQ), Fudan University; Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education (Y-PF, X-CN, YY, X-YC, H-WH, J-XW, Z-FL, JZ, JF, S-JQ), Shanghai, P.R. China; and Cancer Research Institute, Xiangya School of Medicine, Central South University (YC), Hunan, China.
authors.forename: Yi-Peng
authors.initials: YP
authors.lastname: Fu
authors.forename: Xiao-Chun
authors.initials: XC
authors.lastname: Ni
authors.forename: Yong
authors.initials: Y
authors.lastname: Yi
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Cai
authors.forename: Hong-Wei
authors.initials: HW
authors.lastname: He
authors.forename: Jia-Xing
authors.initials: JX
authors.lastname: Wang
authors.forename: Zhu-Feng
authors.initials: ZF
authors.lastname: Lu
authors.forename: Xu
authors.initials: X
authors.lastname: Han
authors.forename: Ya
authors.initials: Y
authors.lastname: Cao
authors.forename: Jian
authors.initials: J
authors.lastname: Zhou
authors.forename: Jia
authors.initials: J
authors.lastname: Fan
authors.forename: Shuang-Jian
authors.initials: SJ
authors.lastname: Qiu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000276:immunology* / Q000401:mortality; D002648:Child; D002681:China / Q000453:epidemiology; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000276:immunology* / Q000401:mortality; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D049451:Nomograms; D012720:Severity of Illness Index; D055815:Young Adult